Alzinova investor relations material

Listen to the latest call from Alzinova

Alzinova AB, a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease. The lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers

  • Ticker

  • Country


Dig deeper into the Alzinova fundamentals on Quartr.